|
Welcome and Overview
Each of the five previous International Conferences on Bipolar Disorder has
represented a unique opportunity for researchers, clinicians and advocates from
around the world to share new information on the pathophysiology, assessment and
treatment of bipolar illness, as well as on psychobiological and psychosocial
vulnerability factors, and recent findings in epidemiology and clinical course.
The meeting attendance has now grown so large that we are moving it to
Pittsburgh’s stunning new convention center on the banks of the Allegheny
River. The amount of new research in bipolar disorder is so extensive that we
are changing the format of the meeting to include multiple concurrent sessions
on rational polypharmacy, neurobiology, the bipolar spectrum, the burden of
bipolar disorder, diagnosis and treatment, and the interplay between advocacy
and research. The conference will be held June 16, 17, and 18, 2005. As in the
past, poster sessions will be held on the evenings of June 16 and 17. The well
received “Rapid Communications” sessions will also be repeated this year.
Presentations during the first two days of the conference will be technical and
geared toward academic researchers and research-oriented clinicians.
Psychiatrists, psychologists, neuroscientists and pharmacologists interested in
bipolar disorder should find the content of this first phase of the conference
useful in their research and practice.
The third
day of the conference, which will include a plenary session on diagnostic and
treatment advances, an advocate/researcher dialogue, and advanced psychotherapy
workshops focusing on cognitive behavioral therapy, family therapy, and
interpersonal psychotherapy, as well as additional workshop sessions, will be
appropriate to audiences that include psychiatrists, psychologists, social
workers, nurses, and other mental health care workers, as well as individuals
who have bipolar disorder and their families. Several of the Saturday workshops
will be focused on issues relevant to advocacy for bipolar disorder.
We look
forward to your participation in the conference.
David J. Kupfer,
M.D.
Educational Objectives:
At
the close of the program, participants should be able to:
-
Describe new
approaches to the pharmacotherapy and psychotherapy of bipolar
disorder.
-
Distinguish
between the issues related to short- and long-term treatment of
bipolar depression.
-
Explain key
issues from the update on neuroscience and clinical advances in
bipolar disorder.
-
Discuss
the life-span implications of bipolar disorder.
Who
Should Attend:
Presentations during
the first two days of the conference will be technical and geared toward
academic researchers and research-oriented clinicians. Psychiatrists,
psychologists, neuroscientists and pharmacologists interested in bipolar
disorder should find the content of this first phase of the conference
useful in their research and practice. The third day of the conference,
which will include a plenary session on diagnostic and treatment
advances, an advocate/researcher dialogue, and advanced psychotherapy
workshops focusing on cognitive behavioral therapy, family therapy, and
interpersonal psychotherapy, as well as additional workshop sessions,
will be appropriate to audiences that include psychiatrists,
psychologists, social workers, nurses, and other mental health care
workers, as well as individuals who have bipolar disorder and their
families. Several of the Saturday workshops will be focused on issues
relevant to advocacy for bipolar disorder.
Top
Course Directors:
Ellen Frank, Ph.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Samuel Gershon, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
David J. Kupfer, M.D.
University of Pittsburgh School of Medicine
Pittsburgh Pennsylvania
Michael E. Thase, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania Top
International Planning Committee
Valentim Gentil, M.D., Ph.D.
University of Sao Paulo Medical School
Sao Paulo, Brazil
Giovanni de Girolamo, M.D.
Department of Mental Health, Bologna and
National Institute of Health
Centre of Epidemiology, Surveillance, and
Health Promotion
Rome, Italy
Guy Goodwin, M.D.
University Department of Psychiatry
Warneford Hospital
Oxford, United Kingdom
Fouzia Laghrissi-Thode, M.D. (unable to
attend)
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Bruno Müller-Oerlinghausen, Dr.med.
Drug Commission of the German Medical
Association
Berlin, Germany
Per Vestergaard, Dr. Med.Sc. (unable to
attend)
Aarhus University, Psychiatric Hospital
Risskov, Denmark
Eduard Vieta, M.D., Ph.D.
University of Barcelona
Barcelona, Spain
Lakshmi N. Yatham, M.B., FRCPC
University of British Columbia Vancouver
British Columbia, Canada
Top
Faculty
Lori Altshuler, M.D.
University of California, Los Angeles
Los Angeles, California
Jules Angst, M.D. (unable to attend)
Zurich University Psychiatric Hospital
Zurich, Switzerland
David A. Axelson, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Mark S. Bauer, M.D.
Brown University School of Medicine
Providence VA Medical Center
Providence, Rhode Island
Anne Berghoefer, Dr.med.
Charite-Universitatsmedizin Berlin
Berlin, Germany
Boris Birmaher, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Charles L. Bowden, M.D.
University of Texas Health Sciences Center at
San Antonio
San Antonio, Texas
Joseph Calabrese, M.D.
Case Western Reserve University School of
Medicine
Cleveland, Ohio
Adriano Camargo
ABRATA
Sao Paulo, Brazil
Giovanni B. Cassano, M.D.
University of Pisa Pisa, Italy
K.N. Roy Chengappa, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania Faculty
Francesc Colom, Psy.D., M.Sc., Ph.D.
University of Barcelona
Barcelona, Spain
J. Raymond DePaulo Jr., M.D.
Johns Hopkins University School of Medicine
Baltimore, Maryland
Wayne Drevets, M.D.
National Institute of Mental Health
Bethesda, Maryland
Omar Elhaj, M.D.
Case Western Reserve University School of
Medicine
Cleveland, Ohio
Andrea Fagiolini, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Robert L. Findling, M.D.
Case Western Reserve University School of
Medicine
Cleveland, Ohio
Debra Frankel, LCSW
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania
Mark Frye, M.D.
University of California, Los Angeles
Los Angeles, California
John R. Geddes, M.D., FRCPsych
University of Oxford Warneford Hospital
Oxford, United Kingdom
Valentim Gentil, M.D., Ph.D.
University of Sao Paulo Medical School
Sao Paulo, Brazil
Elizabeth L. George, Ph.D.
University of Colorado at Boulder
Boulder, Colorado
Giovanni de Girolamo, M.D.
Department of Mental Health, Bologna and
National Institute of Health Centre of
Epidemiology, Surveillance, and Health Promotion Rome, Italy
Guy Goodwin, M.D.
University Department of Psychiatry
Warneford Hospital Oxford, United Kingdom
Della M. Hann, Ph.D.
National Institute of Mental Health
Bethesda, Maryland
Thomas R. Insel, M.D.
National Institute of Mental Health
Bethesda, Maryland
Gordon Johnson, M.D.
University of Sidney
New South Wales, Australia
Paul E. Keck Jr., M.D.
University of Cincinnati College of Medicine
Cincinnati, Ohio
David E. Kelley, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Ronald C. Kessler, M.D.
Harvard Medical School
Boston, Massachusetts
Amy M. Kilbourne, Ph.D., M.P.H.
University of Pittsburgh School of Medicine
VA Pittsburgh Center for Health Equity
Research and Promotion
Pittsburgh, Pennsylvania
Athanasios Koukopoulos, M.D.
Centro Lucio Bini
Rome, Italy
Helena Kraemer, Ph.D.
Stanford University
Palo Alto, California
Ralph W. Kupka, M.D.
Altrecht Institute for Mental Health Care
Utrecht, The Netherlands
Fouzia Laghrissi-Thode, M.D. (unable to
attend)
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Lydia Lewis
Depression and Bipolar Support Alliance
Chicago, Illinois
Husseini K. Manji, M.D.
National Institute of Mental Health
Bethesda, Maryland
Lauren B. Marangell, M.D.
Baylor College of Medicine
Houston, Texas
Susan L. McElroy, M.D.
University of Cincinnati College of Medicine
Cincinnati, Ohio
Kathleen R. Merikangas, Ph.D.
National Institute of Mental Health
Bethesda, Maryland
David J. Miklowitz, Ph.D.
University of Colorado at Boulder
Boulder, Colorado
Philip Mitchell, M.D., FRANZCP, FRCPsych
University of New South Wales
Sydney, Australia
Bruno Müller-Oerlinghausen, Dr.med.
Drug Commission of the German Medical
Association
Berlin, Germany
Benoit H. Mulsant, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Robin Murray, M.D.
Institute of Psychiatry
London, United Kingdom
Willem A. Nolen, M.D., Ph.D.
University of Groningen Medical Centre
Groningen, The Netherlands
Michael Otto, Ph.D.
Boston University
Boston, Massachusetts
Atul Pande, M.D., FRCPC
Pfizer Global Research and Development
Ann Arbor, Michigan
Sagar V. Parikh, M.D., FRCPC
University of Toronto Toronto, Canada
Mary Phillips, M.D.
Institute of Psychiatry
London, United Kingdom
Robert M. Post, M.D.
National Institute of Mental Health
Bethesda, Maryland
Kate Pravera, Ph.D.
Child and Adolescent Bipolar Foundation
Wilmette, Illinois
Noreen Reilly-Harrington, Ph.D.
Harvard Medical School
Boston, Massachusetts
Steven E. Reis, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Laura Roberts, M.D.
Medical College of Wisconsin
Milwaukee, Wisconsin
Gary S. Sachs, M.D.
Harvard Medical School
Boston, Massachusetts
Ihsan Salloum, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Edward M. Scolnick, M.D.
The Broad Institute of Massachusetts Institute
of Technology
Cambridge, Massachusetts
Jan Scott, M.D., FRCPsych
Institute of Psychiatry
London, United Kingdom
Gregory E. Simon, M.D., M.P.H.
Center for Health Studies Group Health
Cooperative
Seattle, Washington
Naomi M. Simon, M.D.
Harvard Medical School
Boston, Massachusetts
Trisha Suppes, M.D., Ph.D.
The University of Texas Southwestern
Medical Center at Dallas
Dallas, Texas
Holly Swartz, M.D.
University of Pittsburgh
School of Medicine Pittsburgh, Pennsylvania
Dawn O. Taylor, Ph.D.
University of Colorado at Boulder
Boulder, Colorado
Mauricio Tohen, M.D., Dr. PH
Lilly Research Laboratories
Indianapolis, Indiana
Harvard Medical School
Boston, Massachusetts
Eduard Vieta, M.D., Ph.D.
University of Barcelona
Barcelona, Spain
Adele Viguera, M.D.
Harvard Medical School
Boston, Massachusetts
Robert M. Wettstein, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Katherine L. Wisner, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Lakshmi N. Yatham, M.B., FRCPC
University of British Columbia
Vancouver, British Columbia, Canada
Top
Rapid
Communication Speakers
Ross J. Baldessarini, M.D.
Harvard Medical School
Boston, Massachusetts
Michael Berk, M.D., Ph.D.
University of Melbourne
Melbourne, Australia
Vivienne Curtis, M.B.B.S., MRC Psych.
Institute of Psychiatry
De Crespigny Park
London, United Kingdom
Terence A. Ketter, M.D.
Stanford University School of Medicine
Stanford, California
Marion Leboyer, M.D., Ph.D.
Paris XII University
Creteil, France
Thomas D. Meyer, Ph.D.
Eberhard Karls-University of Tuebingen
Tuebingen, Germany
Allison C. Nugent, Ph.D.
National Institute of Mental Health Bethesda, Maryland
Martin Preisig, M.D., M.P.H.
Psychiatric University Department
Site de Cery
Prilly-Lausanne, Switzerland
Stephen M. Strakowski, M.D.
University of Cincinnati College of Medicine
Cincinnati, Ohio
Allan H. Young, M.D., Ph.D.
University of New Castle upon Tyne
New Castle upon Tyne, United Kingdom
Carlos A. Zarate Jr., M.D.
National Institute of Mental Health
Bethesda, Maryland
Stevin P. Zung, M.D.
University of Sao Paulo School of Medicine
Sao Paulo, Brazil
Disclosure Statement
Faculty for this
activity have been required to disclose all relationships with any
proprietary entity producing health care goods or services, with the
exemption of non-profit or government organizations and non-health care
related companies.
Lori L. Altshuler,
M.D. Grant/Research Support: Abbott Laboratories
●
Consultant Abbott Laboratories,
AstraZeneca, Bristol-Meyers Squibb, Eli Lilly Company, Forest
Laboratories, Janssen Pharmaceutica.
●
Honoraria: Abbott Laboratories
Bristol-Meyers, Squibb Eli Lilly and Company, Forest Laboratories,
Janssen Pharmaceutica ●
Advisory Board: Abbott
Laboratories, Astra Zeneca, Bristol-Meyers Squibb, Eli Lilly
Company, Forest Laboratories, Janssen Pharmaceutica, Pfizer, Inc.
●
Speakers' Bureau Abbott Laboratories
●
Jules Angst, M.D.
Advisory Board: Eli Lilly and Company, Janssen Pharmaceutica
●
Speaker’s Bureau, AstraZeneca, Eli Lilly and Company,
GlaxoSmithKline, Lundbeck,Foundation Pfizer, Inc.
●
David A. Axelson,
M.D. CME Speakers’ Bureau: AstraZeneca Pharmaceuticals, Janssen
Pharmaceutica ●
Mark S. Bauer, M.D.
Consultant: Pfizer, Inc. ●
Ross J. Baldessarini,
M.D. Research/Grant Support: Auritec Laboratories, Eli Lilly
Laboratories, Janssen Pharmaceutica
●
Consultant: Auritec Laboratories, Eli Lilly Laboratories,
IFI, SpA, Janssen Pharmaceutica, NeuroHealing Pharmaceuticals
●
Ane Berghoefer, Dr.
med. Grant/Research: Support Pfizer, Inc., Schering
Laboratories ●
Consultant: GlaxoSmithKline, Eli Lilly and Company, Sanofi
Aventis
Michael Berk, MBBCh,
MMed, FRANZCP, PhD Grant/Research Support: Bristol-Myers Squibb, Eli
Lilly and Company, Novartis, Organon
●
Consultant: AstraZeneca Pharmaceuticals, Bristol-Myers Squibb,
Eli Lilly and Company, GlaxoSmithKline, Janssen Cilag, Lundbeck
●
CME Speakers’ Bureau: AstraZeneca Pharmaceuticals, Bristol-Myers
Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen-Cilag Lundbeck
Organon, Pfizer, Inc., Sanofi Synthelabo, Solvay Pharmaceuticals, Inc.,
Wyeth
●
Boris Birmaher, M.D.
Grant Research Support: NIMH. ●
Other: Book “New Hope for Bipolar Children”
Charles L. Bowden,
M.D. Grant Research Support: Abbott Laboratories, Bristol-Myers
Squibb Company, Elan Pharmaceuticals, GlaxoSmithKline, Janssen
Pharmaceutica, Lilly Research, National Institute of Mental Health,
Parke Davis R.W., Johnson Pharmaceutical Institute, Smith Kline Beecham,
Stanley Medical Research Foundation
●
Consultant: Abbott Laboratories, GlaxoSmithKline, Janssen
Pharmaceutica, Lilly Research, Sanofi Synthelabo, UCB Pharma, Inc.
●
Speakers Bureau: Abbott Laboratories, AstraZeneca,
GlaxoSmithKline, Janssen Pharmaceutica, Lilly Research, Pfizer,
Inc. ●
Joseph Calabrese,
M.D. Grant/Research Support: Abbott Laboratories, AstraZeneca, Eli
Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, Merck & Co.,
Pfizer, Inc. ●
Consultant: Abbott Laboratories, Astra Zeneca, Bristol-Myers
Squibb Company/ Otsuka, Eli Lilly and Company, GlaxoSmithKline, Janssen
Pharmaceutica, Teva ●
K.N. Roy Chengappa,
M.D. Grant/Research Support: Janssen Pharmaceutica, Ortho McNeil
Pharmaceuticals, Inc. ●
Promotional Speaker’s Bureau: AstraZeneca Pharmaceuticals, Eli
Lilly and Company, Janssen Pharmaceutica
●
CME Speakers’ Bureau: AstraZeneca Pharmaceuticals, Eli
Lilly, Janssen Pharmaceutica ●
Vivienne Curtis,
M.D. Grant/Research Support: AstraZeneca Pharmaceuticals,
Bristol-Myers Squibb, Janssen-Cilag, Sanofi Aventis
●
Consultant: Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly and
Company, GlaxoSmithKline, Janssen-Cilag, Sanofi-Aventis
●
Omar Elhaj, M.D.
Consultant: Abbott Laboratories, AstraZeneca,
Pfizer, Inc.●
Andrea Fagiolini,
M.D. Consultant: Bristol-Meyers Squibb
●
Promotional Speakers’ Bureau:Bristol Meyers Squibb, Pfizer Inc.
●
Robert L. Findling,
M.D. Grant Research Support: Abbott Laboratories, Astra Zeneca,
Bristol Myers Squibb, Celltech-Medeva, Eli Lilly and Company, Forest
Pharmaceuticals, Inc., GlaxoSmithKline, Johnson & Johnson, Inc., New
River, Novartis, Otsuka, Pfizer, Inc., Shire ,Solvay Pharmaceuticals,
Inc. , Wyeth ●
Consultant: Abbott Laboratories, Astra Zeneca, Bristol
Myers Squibb, Celltech-Medeva, Forest Pharmaceuticals, Inc.,
GlaxoSmithKline, Johnson & Johnson, Inc., Eli Lilly and Company, New
River, Novartis, Otsuka, Pfizer, Inc., Sanofi-Synthelabo Shire, Wyeth
●
Speaker’s Bureau: Shire ●
Ellen Frank, Ph.D.
Grant Research Support: National Institute of Mental Health, The
Pittsburgh Foundation, Forrest Research Institute
●
Consultant: Pfizer Italia, Pfizer, Inc., Eli Lilly and Company
●
Mark A. Frye, M.D.
Research Grant Support: Abbott Laboratories, American Foundation for
Suicide Prevention, GlaxoSmithKline, National Institute of Mental
Health, Pfizer Inc., Solvay Pharmaceuticals, Stanley Medical
Research Institute ●
Consultant: Abbott Laboratories, Astra Zeneca Pharmaceuticals,
Bristol Myers Squibb, Cephalon, Elan Pharmaceuticals, Eli Lilly and
Company, GlaxoSmithKline, Janssen Pharmaceutica-Cilag, Johnson &
Johnson, PRD Novartis, Ortho-McNeil Pharmaceuticals, Otsuka
Pharmaceuticals, Pfizer Inc., UCB Pharma
●
Speakers’ Bureau: Abbott Laboratories, AstraZeneca,
Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen
Pharmaceutica-Cilag, Novartis, Ortho McNeil, Otsuka Pharmaceuticals
●
John R. Geddes,
M.D., FRCPsych Grant/Research Support: GlaxoSmithKline,
Sanofi-Aventis ●
Valentim Gentil,
M.D., Ph.D. Consultant: Bristol-Myers Squibb, Eli Lilly and Company,
Gervier, Pfizer, Inc., Wyeth ●
Samuel Gershon, M.D.
Consultant: NIA Scientific Advisory Committee, NYU ACOS
●
Guy Goodwin, M.D.
Grant Research Support: Sanofi-Aventis
●
Consultant: Bristol-Myers Squibb, Sanofi- Aventis, Servier,
Solvay/Wyeth ●
CME Speakers’ Bureau: Astra ZenecaPharmaceuticals,
Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline,
Lundbeck, Sanofi-Aventis ●
Gordon Johnson, M.D.
Grant Research Support: Astra Zeneca Pharmaceuticals, GlaxoSmithKline,
Organon ●
Consultant: Eli Lilly and Company, Ramsay Healthcare, Sanofi
Aventis, Servier ●
Paul E. Keck, Jr.,
M.D. Research Grant Support: Abbott Laboratories, American Diabetes
Association, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company
●
GlaxoSmithKline, Elan, Eli Lilly and Company,
Janssen Pharmaceutica, National Institute of Mental Health,
National Institute of Drug Abuse, Organon, Ortho-McNeil Pharmaceutical,
Inc., Pfizer, Inc., UCB Pharma ●
Consultant: Abbott Laboratories, Astra Zeneca
Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen
Pharmaceutica, Jazz Pharmaceutica, Eli Lilly and Company, Novartis,
Pfizer, Shire, Wyeth ●
Ronald C. Kessler,
Ph.D. Grant/Research Support: Bristol-Myers Squibb, Eli Lilly and
Company, GlaxoSmithKline, Pfizer, Inc., Ortho McNeil Pharmaceutical,
Inc. ●
Consultant: Bristol-Myers Squibb, Eli Lilly and
Company, GlaxoSmithKline, Pfizer, Inc., Ortho McNeil Pharmaceutical,
Inc. ●
Terrence A. Ketter,
M.D. Grant/Research Support: Abbott Laboratories: AstraZeneca:
Bristol-Myers Squibb, Elan Pharmaceuticals, Eli Lilly and Company,
GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Shire Laboratories
●
Consultant: Abbott Laboratories, AstraZeneca, Bristol-Myers
Squibb, Cephalon, Elan Pharmaceuticals, Eli Lilly and Company,
GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Pfizer, Inc., Shire
Laboratories ●
Lecture Honoraria: Abbott Laboratories, AstraZeneca,
Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen
Pharmaceutica, Novartis, Pfizer, Inc.
●
David J. Kupfer,
M.D. Consultant: Servier Amerique
●
Other: Eli Lilly and Company
●
F. Hoffman – La Roche Ltd., Forest Pharmaceuticals, Inc.,
Pfizer, Inc. ●
Ralph W. Kupka, M.D.
Consultant AstraZeneca Pharmaceuticals, Eli Lilly and Company, Janssen
Pharmaceutica-Cilag ●
Fouzia-Laghrissi-Thode, M.D. Stockholder: Novartis Roche
●
Other: Roche employee●
Lauren B. Marangell,
M.D. Grant/Research Support: Cyberonics, Inc. (Device Company), Eli
Lilly and Company, Neuronetics (Device Company)
●
Consultant: AstraZeneca, Bristol-Myers Squibb, Cyberonics, Eli
Lilly and Company, Forest Pharmaceuticals, GlaxoSmithKline, Medtronics,
Novartis, Pfizer, Inc., Wyeth-Ayerst Laboratories
●
Other: In addition, several companies have given
educational grants for CME programs at Baylor College of Medicine. These
checks are made payable to Baylor College of Medicine and handled though
the Office of Continuing Medical Education.
●
Susan L. McElroy,
M.D. Grant/Research Support: AstraZeneca Pharmaceuticals,
Bristol-Myers Squibb Company, Eli Lilly and Company, Esai Inc., Forest
Pharmaceuticals, Inc., Ortho McNeil Pharmaceutical, Inc., Pfizer, Inc.
Sanofi-Synthelabo Consultant Abbott Laboratories Bristol-Myers Squibb
Company Eli Lilly and Company GlaxoSmithKline Janssen Pharmaceutica
Novartis Ortho-McNeil Wyeth-Ayerst
●
David J, Miklowitz,
Ph.D. CME Speakers’ Bureau: Eli Lilly and Company
●
Philip Mitchell,
M.D., FRANZCP, FRCPsych Consultant: AstraZeneca, Eli Lilly and
Company, GlaxoSmithKline, Sanofi-Aventis
●
Benoit H. Mulsant,
M.D. Grant/Research Support: National Institute of Health
● Consultant: AstraZeneca
Pharmaceuticals, Bristol-Myers Squibb Company, Forest Pharmaceuticals,
Inc., Fox Learning System, Janssen Pharmaceutica
● Speakers’ Bureau:
AstraZeneca, Forest Pfizer/Eisai ●
Stocks: Azko-Nobel Alkermes
● AstraZeneca,
Biogen, Idec Celsion,
Elan, Eli Lilly and Company, Forest Pharmaceuticals, Inc., Immune
Response, Pfizer, Inc. ●
Honoraria: AstraZeneca, Forest Pharmaceuticals, Inc., Lundbeck,
Pfizer/Eisai ●
Robin Murray, M.D.
Grant/Research Support: AstraZeneca, Eli Lilly and Company
● CME Speakers’ Bureau:
AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and
Company, Janssen Pharmaceutica, Sanofi
●
Willem A. Nolen,
M.D., Ph.D. Grant/Research Support: AstraZeneca, GlaxoSmithKline,
Wyeth ● Consultant:
AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson,
Pfizer, Inc. ● Promotional
Speakers’ Bureau: AstraZeneca Pharmaceuticals, Eli Lilly and Company,
GlaxoSmithKline, Johnson & Johnson, Organon
●
Michael Otto, Ph.D.
Grant/Research Support: GlaxoSmithKline
●
Atul C. Pande M.D.
Stockholder: Pfizer, Inc. ●
Other: Full-time employee Pfizer, Inc.
●
Sagar V. Parikh,
M.D., FRCP Grant/Research Support: AstraZeneca ,
Biovail, Eli Lilly & Company,
Janssen-Ortho, Inc., Novartis, Wyeth
● Consultant: AstraZeneca,
Biovail, Eli Lilly and Company, Janssen-Ortho, Inc., Novartis, Wyeth
● CME Speakers’ Bureau:
AstraZeneca, Biovail, Eli Lilly and Company, Wyeth
●
Mary L. Phillips,
M.D. Grant/Research Support: Merck & Co.
●
Martin Preisig,
M.D., M.P.H. Grant/Research Support: GlaxoSmithKline
●
Noreen
Reilly-Harrington, Ph.D. Grant/Research Support:
GlaxoSmithKline ●
Laura Roberts, M.D.
Grant/Research Support: NIDA DOE ●
Other: Owner: EthicsRx ●
Gary S. Sachs, M.D.
Grant/Research Support: Abbott Laboratories, Janssen Pharmaceutica
● Consultant: Abbott
Laboratories, GlaxoSmithKline ●
Janssen Pharmaceutica, Eli Lilly and Company, Bristol-Myers Squibb,
Novartis Elan, Sanofi-Aventis, Sigma-Tau AstraZeneca
● Honoraria: Abbott
Laboratories, Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly and Company,
GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Pfizer, Inc., Sanofi,
Solvay Pharmaceuticals, Inc. ●
Ihsan M. Salloum,
M.D., M.P.H. Grant/Research Support: Abbott Laboratories, Alkermese,
Inc., Drug Abuse Sciences, Inc., Lipha Pharmaceuticals, Mental
Illness Research Education and Clinical Center (MIRECC), National
Institute of Alcohol Abuse and Alcoholism, National Institute on Drug
Abuse, National Institute of Mental Health, Oy Contral Pharmaceuticals,
Ortho McNeil Pharmaceuticals, Veteran Integrated Service Network 4
● Consultant: Abbott
Laboratories, AstraZeneca, Forest Laboratories, Cephalon
● Promotional Speakers’
Bureau: Janssen Pharmaceutica ●
CME Speakers’ Bureau: Abbott Laboratories
●
Edward M. Scolnick,
M.D. Consultant: Millipore Corporation, MPM Capital, Renovis, Inc.,
TransForm Pharmaceuticals ●
Stockholder: Merck and Co., Renovis, Inc., TransForm Pharmaceuticals,
Oscient ●
Jan Scott, M.D.
Grant/Research Support: AstraZeneca Pharmaceuticals
● CME Speakers’ Bureau:
Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline,
Janssen Pharmaceutica ●
Gregory E. Simon,
M.D., M.P.H. Grant/Research Support: Eli Lilly and Company, Solvay
Pharmaceuticals, Wyeth Ayerst Pharmaceuticals
● Consultant: Pfizer
Pharmaceuticals ●
Naomi M. Simon, M.D.
Grant/Research Support: AstraZeneca, Cephalon, Forest Laboratories,
GlaxoSmithKline, Janssen, Eli Lilly and Company, UCB-Pharma
● CME Speaker’s Bureau:
Forest Laboratories, Pfizer, Inc.
●
Stephen M.
Strakowski, M.D. Grant/Research Support: AstraZeneca Pharmaceuticals
Bristol-Myers Squibb, Eli Lilly and Company, Forest Laboratories,
Janssen Pharmaceutica ●
Consultant: AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Eli Lilly
and Company, OrthoMcNeil, ●
CME Speakers’ Bureau: AstraZeneca Pharmaceuticals, Bristol-Myers Squibb,
Eli Lilly and Company, Forest Laboratories, Janssen Pharmaceutica,
OrthoMcNeil ●
Trisha Suppes. M.D.,
Ph.D. Grant/Research Support: Abbott Laboratories, AstraZeneca
Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline
Pharmaceuticals, Janssen Pharmaceutica, National Institute of Mental
Health, Novartis, Robert Wood Johnson Pharmaceutical Research Institute,
The Stanley Medical Research Institute
● Consultant: Abbott
Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company,
Eli Lilly Laboratories, GlaxoSmithKline Pharmaceuticals, Janssen
Pharmaceutica, Johnson & Johnson Pharmaceutical, Novartis
Pharmaceutical, Pfizer Pharmaceutical Research Institute (PRI), Ortho
McNeil Pharmaceutical, Shire Pharmaceutical, Solvay Pharmaceutical, UCB
Pharmaceuticals ●
Holly Swartz, M.D.
Grant/Research Support: National Institute of Mental Health, Staunton
Farms Foundation ●
Consultant Eli Lilly and Company ●
Promotional Speakers’ Bureau
● Pfizer
● CME Speakers’ Bureau Eli
Lilly and Company Pfizer, Inc.
Michael E. Thase,
M.D. Consultant AstraZeneca Pharmaceuticals Bristol-Myers Squibb
Company Cephalon, Inc. Cyberonics, Inc. Eli Lilly and Company Forest
Laboratories, Inc. GlaxoSmithKline Janssen Pharmaceutica Novartis
Organon Pfizer, Inc. Wyeth ●
Speakers’ Bureau: AstraZeneca Pharmaceuticals, Eli Lilly and
Company ,
GlaxoSmithKline●
Organon, Wyeth, Pharmaceuticals
●
Mauricio Tohen, M.D.
Dr. P.H. Stockholder: Eli Lilly and Company
● Other Full-time employee
Eli Lilly and Company ●
Eduard Vieta, M.D.,
Ph.D. Grant/Research Support: Astra-Zeneca Pharmaceuticals,
Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen-Cilag,
Novartis, Pfizer, Inc., Sanofi ●
Consultant: Astra-Zeneca Pharmaceuticals, Bristol-Myers Squibb,
Eli Lilly and Company, Janssen-Cilag, Novartis, Pfizer, Inc., Sanofi
● Promotional Speakers’
Bureau: Astra-Zeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly
and Company, Janssen-Cilag Pfizer, Inc.
●
Per Vestergaard, Dr.
Med. Sc. Consultant: Pfizer, Inc.
● Stockholder NOVO
Adele C. Vigueira,
M.D. Promotional Speakers’ Bureau: GlaxoSmithKline
●
Katherine L. Wisner,
M.D. Promotional Speakers’ Bureau: Pfizer, Inc., GlaxoSmithKline
●
Lakshmi N. Yatham,
MB, FRCP Grant/Research Support: AstraZeneca Pharmaceuticals,
Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen
Pharmaceutica, Novartis, Pfizer, Inc.
● Consultant: AstraZeneca
Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company,
GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Pfizer, Inc.●
Promotional Speakers’ Bureau: AstraZeneca Pharmaceuticals, Bristol-Myers
Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica,
Novartis, Pfizer, Inc. ●
CME Speakers’ Bureau: AstraZeneca Pharmaceuticals, Bristol-Myers Squibb,
Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, Novartis,
Pfizer, Inc.●
No significant
financial relationships with commercial entities were disclosed by:
Adriano Camargo
●
Giovanni B. Cassano, M.D.
●
Francesc Colom, PsyD, MSc, Ph.D.
●
J. Raymond DePaulo, Jr., M.D.
●
Wayne Drevets, M.D.
● Debra Frankel,
LCSW ●
Elizabeth George, Ph.D.
●
Giovanni de Girolamo, M.D.
●
Della M. Hann, Ph.D.
●
Thomas R. Insel, M.D.
●
David E. Kelly, M.D.
●
Amy M. Kilbourne, Ph.D., M.P.H.
●
Athanasios Koukopoulos, M.D.
●
Helena C. Kraemer, Ph.D.
●
Marion Leboyer, M.D., Ph.D.
●
Lydia Lewis ●
Husseini J. Manji, M.D.
●
Kathleen R. Merikangas, Ph.D.
●
Thomas D. Meyer, Ph.D.
●
Bruno Müller-Oerlinghausen, M.D.
●
Allison Nugent, Ph.D.
●
Robert M. Post, M.D.
●
Kate Pravera, Ph.D.
● Steven E. Reis,
M.D. ●
Dawn O. Taylor, Ph.D.
●
Robert M. Wettstein, M.D.
●
Allan H. Young, MB.ChB., MRCPsych, Ph.D.
●
Carlos A. Zarate, Jr., M.D.
●
Stevin Parreira Zung, M.D.
The information
presented at this CME program represents the views and opinions of the
individual presenters, and does not constitute the opinion or
endorsement of, or promotion by, the UPMC Center for Continuing
Education in the Health Sciences, UPMC Health System or Affiliates and
University of Pittsburgh School of Medicine. Reasonable efforts have
been taken intending for educational subject matter to be presented in a
balanced, unbiased fashion and in compliance with regulatory
requirements. However, each conference attendee must always use his/her
personal judgment when considering further application of this
information, particularly as it may relate to patient diagnostic or
treatment decisions including, without limitation, FDA-approved uses and
any off-label uses.
Acknowledgements
We would like to acknowledge the
following companies for their generous support of this program:
Abbott Laboratories
AstraZeneca
Pharmaceuticals
Bristol-Myers Squibb
Company
Forest Laboratories
GlaxoSmithKline
Janssen
Pharmaceutica
Eli Lilly and
Company
Pfizer, Inc.
Solvay
Pharmaceuticals
Wyeth
Pharmaceuticals |
|
